Premium
Clinical Application of Dih‐drotestosterone (DHT) Binding Assa‐ of Cultured Skin Fibroblasts for the Prospective Differential Diagnosis of Testicular Feminization S‐ndrome (TFS)
Author(s) -
Wakimoto Hiroshi,
Takaasu Susumu,
Kurachi Hirohisa,
Komura Hiroko,
Miake Akira,
Aono Toshihiro,
Tanizawa Osamu,
Matsumoto Keishi
Publication year - 1985
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1985.tb00763.x
Subject(s) - differential diagnosis , testicular feminization , endocrinology , medicine , biology , pathology , androgen receptor , prostate cancer , cancer
The present stud‐ was conducted to evaluate the usefulness of dih‐drotestosterone (DHT) binding assa‐ of skin fibroblasts for the differential diagnosis in infants of testicular feminization s‐ndrome (TFS) from other disorders with genital anomalies. DHT binding was measured in the fibroblasts derived from the patients with intersex or genital anomalies such as TFS, incomplete TFS, pure gonadal agenesis, retentio testis, Klinefelter's s‐ndrome, testicular d‐sgenesis, adrenogenital s‐ndrome, and Turner's s‐ndrome. All patients except the TFS patients exhibited normal binding capacit‐ in fibroblasts from either genital or nongenital skins. The patients with TFS were 3 and 6 ‐ear‐old siblings whose diagnosis had not been made completel‐ b‐ g‐necological examination and routine laborator‐ tests, but the binding assa‐ contributed to making the exact diagnosis of these patients. DHT binding of skin fibroblasts from normal males and females was 11.5±8.6 (S. D.) fmoles/mg cell protein in nongenital skin, whereas the DHT binding assa‐ of these patients showed that the maximal number of binding sites was under 0.5 fmoles/mg cell protein. These results suggest that DHT binding assa‐ of skin fibroblasts is useful also for the prospective differential diagnosis of TFS in infant and prepubertal patients and that treatment for TFS might be planned from infanc‐.